0
Your cart

Your cart is empty

Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology

Buy Now

Selective Activation of Drugs by Redox Processes (Hardcover, New) Loot Price: R2,591
Discovery Miles 25 910
Selective Activation of Drugs by Redox Processes (Hardcover, New): G.E. Adams, A. Breccia, E.M. Fielden, P. Wardman

Selective Activation of Drugs by Redox Processes (Hardcover, New)

G.E. Adams, A. Breccia, E.M. Fielden, P. Wardman

Series: NATO Science Series A, v. 198

 (sign in to rate)
Loot Price R2,591 Discovery Miles 25 910 | Repayment Terms: R243 pm x 12*

Bookmark and Share

Expected to ship within 12 - 17 working days

Donate to Against Period Poverty

Characteristics of Hypoxic Cells that Enhance their Susceptibility to Chemical Injury.- Prediction and Measurement of Redox Properties of Drugs and Biomolecules.- Metal-Catalyzed Redox Processes in Biological Systems and Drug Activation.- Redox Systems Generated by Electro-chemical Oxidations and Reductions.- The Role of DNA Damage in the Bioreductive Action of 2-Nitroimidazoles.- Redox Properties of Radiation Induced Free Radicals.- Reduction of Bleomycin-Fe by Reductases and Active Oxygen Formation.- Redox Activation of Drugs by the Red Blood Cell Membrane.- Induction of Stress Proteins and Drug Resistance by Hypoxia and Applications of Magnetic Resonance Spectroscopy and Cryospectrophotometry for Detecting Hypoxia in Tumors.- Mechanisms of Activation of Mitomycin C and AZQ in Aerobic and Hypoxic Mammalian Cells.- Molecular Interactions and Biological Effects of the Products of Reduction of Nitroimidazoles.- Redox Activation of Benzotriazine N-oxides: Mechanisms and Potential as Anticancer Drugs.- Nitroacridines and Nitroquinolines as DNA-affinic Hypoxia-selective Cytotoxins.- Metabolic Effects of Hypoxic Cell Sensitizers.- Does Ro-03-8799 Concentration in Human Tumour Xenografts Predict Radiosensitization? Comparison with SR-2508.- Enzyme-directed Bioreductive Drug Development.- Improved Treatment of Tumours in vivo by Combining the Bioreductive Drug, RSU-1069, Hydralazine and Hyperthermia.- Assessment of Bioreductive Drug Toxicity in vitro and in Experimental Tumours in vivo.- Activity of Bioreductive Agents in Human and Rodent Tumor Cells.- The Control of Tumour Oxygenation in Mice: The Importance of Tumour Site.- Critical Events in the Toxicity of Redox Active Drugs.- The Reductive Activation of Nitroimidazoles; Modification by Oxygen and other Redox-active Molecules in Cellular Systems.- Fluorescent Probes for Hypoxia: Chemical Aspects.- Toxicity of Metal Complexes with Radiosensitizing Properties.- Effects on DNA of Bioreducible Nitroimidazole and Benzotriazine Drugs.- Response of Repair and Reduction Deficient Mutants to Agents Requiring Bioreduction.- Bioreductive Drugs and Radiation: Pharmacokinetics and Clinical Trials of Etanidazole Radiosensitizer.- The Oncogenic Potential of Bioreductive Drugs.- Adduct Formation by 2-Nitroimidazole in Mammalian Cells: Optimization of Markers for Tissue Oxygenation.- Tumour Blood Flow and its Modulation: Implications for Bioreductive Drug Activity in vivo.- Poster Presentations.- Participants.

General

Imprint: Kluwer Academic / Plenum Publishers
Country of origin: Netherlands
Series: NATO Science Series A, v. 198
Release date: 1991
First published: February 1991
Editors: G.E. Adams • A. Breccia • E.M. Fielden • P. Wardman
Dimensions: 230mm (L)
Format: Hardcover
Pages: 360
Edition: New
ISBN-13: 978-0-306-43735-9
Categories: Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > General
LSN: 0-306-43735-X
Barcode: 9780306437359

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners